MendaCel, Inc.
MendaCel, Inc is pioneering the future of wound care with its proprietary device, MendaCel™, which integrates proven treatment modalities into a dynamic delivery system for at-home care. The company is advancing its innovative solutions with patent-pending technology, verified manufacturability, and regulatory exemptions. MendaCel is actively engaged in funding and partnership opportunities, including a successful NIH Phase 1 SBIR/STTR application and a pending US Army MRDC BAA pre-application.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Proprietary at‑home wound care device (prototype, patent‑pending)
A prototype medical device that combines multiple treatment modalities into a dynamic delivery system designed for at‑home wound care. Patent‑pending and reported as working prototypes; positioned under an FDA 510(k) exemption.
Proprietary at‑home wound care device (prototype, patent‑pending)
A prototype medical device that combines multiple treatment modalities into a dynamic delivery system designed for at‑home wound care. Patent‑pending and reported as working prototypes; positioned under an FDA 510(k) exemption.
Expertise Areas
- Wound care device development
- Medical device prototyping
- Multimodal therapeutic delivery
- Regulatory pathway assessment (FDA exemption)
Key Technologies
- At‑home medical device systems
- Multimodal therapeutic delivery platforms
- Prototype fabrication and validation
- Regulatory submission processes (FDA 510(k) pathways)
News & Updates
MendaCel will be exhibiting at Med-Tech World Malta in November 2024.
MendaCel will be virtually attending the Boston RESI conference in September 2024.
An article discussing MendaCel's introduction of a cutting-edge wound care device.
MendaCel will be exhibiting at Med-Tech World Malta in November 2024.
MendaCel will be virtually attending the Boston RESI conference in September 2024.
An article discussing MendaCel's introduction of a cutting-edge wound care device.